EDIT Gilmore Neil O'Neill sells $28K worth of shares
Mar 06, 2025, 5:32 AM
0.00%
What does EDIT do
Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
Gilmore Neil O'Neill sold 16,632 shares of EDIT on 4 March at $1.71 per share, worth a total of $28K. They now own 295,474 EDIT shares, or a 5% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
